ESR1 and neoplasm: Vici et al. retrospectively examined 872 patients with triple-positive breast cancer treated with adjuvant chemotherapy with or without trastuzumab and found that tumors expressing both ER and PR in >50% of total tumour cells were associated with poorer relapse-free survival and breast-cancer specific survival [44].